Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPC
Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Clinical Pearls:
- Ipilimumab is an immune modulator that works by breaking tolerance and stimulating the immune system so that it can recognize and attack the prostate cancer
- Since ipilimumab is not specific to a cancer antigen, it causes side effects that are related to an overactive immune system
- The analysis of the trial found that the side effect profile of ipilimumab in prostate cancer is similar to what was previously described in melanoma, where the drug is approved
- Standard approaches to the management of these side effects are almost always effective
ENVISION Trial of UGN-102 Shows Durable Responses in LG-IR-NMIBC
February 3rd 2025Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Read More
